A5102828117- Acute Myeloid Leukemia Research
- Retinoids in leukemia and cellular processes
- MicroRNA in disease regulation
- Nuclear Structure and Function
- Ubiquitin and proteasome pathways
- RNA Research and Splicing
- RNA Interference and Gene Delivery
- RNA modifications and cancer
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Cancer-related molecular mechanisms research
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Genomics and Chromatin Dynamics
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Extracellular vesicles in disease
- Immune cells in cancer
- interferon and immune responses
- Drug Transport and Resistance Mechanisms
- CAR-T cell therapy research
- Computational Drug Discovery Methods
- Peroxisome Proliferator-Activated Receptors
- Neutropenia and Cancer Infections
- NF-κB Signaling Pathways
National Center for Tumor Diseases
2019-2025
University Hospital Carl Gustav Carus
2021-2025
Deutschen Konsortium für Translationale Krebsforschung
2023-2025
Helmholtz-Zentrum Dresden-Rossendorf
2023-2025
German Cancer Society
2023-2025
Technische Universität Dresden
2011-2025
German Cancer Research Center
2023
Nationales Centrum für Tumorerkrankungen Dresden
2023
University Hospital Leipzig
2012-2018
Leipzig University
2013-2018
Targeted therapies are effective in treating cancer, but success depends on identifying cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact of pathway activation microRNA (miRNA) expression patterns. Interestingly, discover that miRNAs capable inhibiting key members activated pathways frequently diminished. Building this observation, develop an approach integrates a low-miRNA-expression signature identify druggable target genes cancer. We train and...
In acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) treatment induces granulocytic maturation and complete remission of leukemia. microRNAs are known to be critical players in the formation leukemic phenotype. this study, we report downregulation miR-181a/b gene cluster APL blasts NB4 cells upon ATRA as a key event drug response. We found that expression was activated by PML/RARα oncogene transgenic knock-in mice, an observation confirmed extended evidence enhanced patient...
Transcription factor C/EBPα is a master regulator of myelopoiesis and its inactivation associated with acute myeloid leukemia. Deregulation by microRNAs during granulopoiesis or leukemia development has not been studied. Here we show that oncogenic miR-182 strong C/EBPα. Moreover, identify regulatory loop between miR-182. While blocks expression direct promoter binding differentiation, enforced reduces protein level impairs in vitro vivo. In addition, highly elevated particularly patients...
Relapse in acute myeloid leukemia (AML) is driven by resistant subclones that survive chemotherapy. It assumed these resilient leukemic cells can modify their proliferative behavior entering a quiescent-like state, similar to healthy hematopoietic stem (HSCs). These dormant evade the effects of cytostatic drugs primarily target actively dividing cells. Although quiescence has been extensively studied hematopoiesis and various solid cancers, its role AML remained unexplored. In this study, we...
Colorectal cancer (CRC) ranks as the third most commonly diagnosed worldwide and is second leading cause of cancer-related mortality. Recent studies have highlighted critical role long non-coding RNAs (lncRNAs) in CRC development, influencing processes such proliferation, invasion, therapy resistance. However, functional roles annotated lncRNAs remain poorly understood, underscoring need to uncover novel that may impact initiation, progression, treatment response. To identify involved cell...
Abstract Targeted panel sequencing of known genetic driver alterations is an established part the initial clinical diagnostic routine for many tumors. However, exploratory advanced and rare cancers remains experimental. MASTERsg a prospective broad program that utilizes TSO500 TST170 DNA/RNA assays to identify therapeutically relevant in patients with cancers. The pipeline detects copy number variations (CNVs) by dividing CNV caller’s raw data into gene-specific bins, each consisting 50-250...
Abstract Hematopoiesis, the formation of blood cells from hematopoietic stem (HSC), is a highly regulated process. Since discovery microRNAs (miRNAs), several studies have shown their significant role in regulation system. Impaired expression miRNAs leads to disrupted cellular pathways and particular causes loss ability. Here, we report previously unrecognized function miR-143 granulopoiesis. Hematopoietic undergoing granulocytic differentiation exhibited increased expression. Overexpression...
Abstract Lysine acetyltransferase 2 A (KAT2A) plays a pivotal role in epigenetic gene regulation across various types of cancer. In colorectal cancer (CRC), increased KAT2A expression is associated with more aggressive phenotype. Our study aims to elucidate the molecular underpinnings dependency CRC and assess consequences depletion. We conducted comprehensive analysis by integrating CRISPR-Cas9 screening data genomics, transcriptomics, global acetylation patterns cell lines pinpoint markers...
Active BCR related (ABR) gene deactivates ras-related C3 botulinum toxin substrate 1 (RAC1), which plays an essential role in regulating normal hematopoiesis and leukemia. gene, closely to ABR, acts as a tumor suppressor chronic myeloid leukemia has overlapping functions with ABR. Evidence for putative of ABR been shown several solid tumors, deletion is present. Our results show downregulation AML. A block prevents differentiation leads repression the transcription factor C/EBPα, major...
Abstract Protein-coding and non-coding genes like miRNAs tightly control hematopoietic differentiation programs. Although are frequently located within introns of protein-coding genes, the molecular interplay between intronic their host is unclear. By genomic integration site mapping gamma-retroviral vectors in genetically corrected peripheral blood from gene therapy patients, we identified EVL/MIR342 locus as a hotspot for therapeutic vector insertions indicating its accessibility...
Abstract About 25% of melanoma harbor activating NRAS mutations, which are associated with aggressive disease therefore requiring a rapid antitumor intervention. However, no efficient targeted therapy options currently available for patients NRAS‐mutant melanoma. MEK inhibitors (MEKi) appear to display moderate activity and also immunological effects in melanoma, providing an ideal backbone combination treatments. In our study, the MEKi binimetinib, cobimetinib trametinib combined BRAF...
Abstract Background Lysine acetyltransferase 2A (KAT2A) plays a pivotal role in epigenetic gene regulation across various types of cancer. In colorectal cancer (CRC), upregulation KAT2A is associated with more aggressive phenotype. Our study aims to elucidate the molecular underpinnings dependency CRC and assess consequences depletion. Methods We conducted comprehensive analysis by integrating CRISPR-Cas9 screening data genomics, transcriptomics, global acetylation patterns cell lines...
Background: In 2022, the ELN risk stratification for patients (pts) with acute myeloid leukemia (AML) has been updated. The key changes of revised recommendations are as follows: i) bZIP in-frame CEBPA mutations now considered favorable-risk (ELN22fav), irrespective monoallelic/biallelic mutation status; ii) pts FLT3-ITD intermediate-risk (ELN22int), allelic ratio or NPM1 and iii) alterations in myelodysplasia-related (MR) genes (BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1 ZRSR2) categorized...
Despite the constant development of innovative therapeutic options for hematological malignancies, gold-standard therapy regimen curative treatment often includes allogeneic hematopoietic stem cell transplantation (HSCT). The graft-versus-leukemia effect (GVL) is one main goals that arises from HSCT. On other hand, graft-versus-host disease (GVHD) still and most serious complications following In acute myeloid leukemia (AML), HSCT together with high-dose chemotherapy used as a option. An...